keyword
MENU ▼
Read by QxMD icon Read
search

Rosuvastatin in Chronic Kidney Disease

keyword
https://www.readbyqxmd.com/read/28960806/regional-evidence-and-international-recommendations-to-guide-lipid-management-in-asian-patients-with-type-2-diabetes-with-special-reference-to-renal-dysfunction
#1
REVIEW
Titus Wl Lau, Kevin Ek Tan, Jason Cj Choo, T G Ng, Tavintharan S, Juliana C N Chan
The anticipated increase in the prevalence and incidence of type 2 diabetes in Asia, and its associated cardiovascular-renal complications will place a significant burden on patients, caregivers and society. Despite the proven effectiveness of lipid management in reducing these complications, there are major treatment gaps especially in Asian patients with young-onset diabetes and chronic kidney disease. Recent international guidelines recommended the adoption of absolute risk estimation of atherosclerosis and cardiovascular disease to guide treatment intensity...
September 28, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28682890/efficacy-of-short-term-moderate-or-high-dose-rosuvastatin-in-preventing-contrast-induced-nephropathy-a-meta-analysis-of-15-randomized-controlled-trials
#2
REVIEW
Min Liang, Shicheng Yang, Naikuan Fu
BACKGROUND: The prophylactic efficacy of statin pretreatment for the prevention of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) remains controversial. The aim of the study was to perform a meta-analysis of randomized controlled trials (RCTs) to assess the effectiveness of short-term moderate or high-dose rosuvastatin pretreatment in preventing CIN. METHODS: We included RCTs comparing short-term moderate or high-dose rosuvastatin treatment versus low-dose rosuvastatin treatment or placebo for preventing CIN...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#3
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28223836/dyslipidemia-in-patients-with-chronic-kidney-disease-etiology-and-management
#4
REVIEW
Ivana Mikolasevic, Marta Žutelija, Vojko Mavrinac, Lidija Orlic
Patients with chronic kidney disease (CKD), including those with end-stage renal disease, treated with dialysis, or renal transplant recipients have an increased risk for cardiovascular disease (CVD) morbidity and mortality. Dyslipidemia, often present in this patient population, is an important risk factor for CVD development. Specific quantitative and qualitative changes are seen at different stages of renal impairment and are associated with the degree of glomerular filtration rate declining. Patients with non-dialysis-dependent CKD have low high-density lipoproteins (HDL), normal or low total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol, increased triglycerides as well as increased apolipoprotein B (apoB), lipoprotein(a) (Lp (a)), intermediate- and very-low-density lipoprotein (IDL, VLDL; "remnant particles"), and small dense LDL particles...
2017: International Journal of Nephrology and Renovascular Disease
https://www.readbyqxmd.com/read/27671328/clinical-implications-of-switching-lipid-lowering-treatment-from-rosuvastatin-to-other-agents-in-primary-care
#5
Furio Colivicchi, Michele Massimo Gulizia, Laura Franzini, Giuseppe Imperoli, Lorenzo Castello, Alessandro Aiello, Claudio Ripellino, Nazarena Cataldo
INTRODUCTION: Switching from any statin to another non-equipotent lipid lowering treatment (LLT) may cause a low-density lipoprotein cholesterol increase and has been associated with a higher probability of negative cardiovascular outcomes. The aim of the study was to assess the impact of switching from rosuvastatin to any other LLT on clinical outcomes in primary care. METHODS: This was a retrospective analysis based on data from IMS Health Longitudinal Patient Database, which is a general practice database including information of more than 1...
November 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27162677/short-term-rosuvastatin-therapy-prevents-contrast-induced-acute-kidney-injury-in-female-patients-with-diabetes-and-chronic-kidney-disease-a-subgroup-analysis-of-the-track-d-study
#6
Jing Li, Yi Li, Biao Xu, Guoliang Jia, Tao Guo, Dongmei Wang, Kai Xu, Jie Deng, Yaling Han
BACKGROUND: Female patients are at higher risk of contrast-induced acute kidney injury (CIAKI) compared to males. In the multicenter, prospective, TRACK-D study, short-term rosuvastatin has proven effectively reduce CIAKI in patients with type 2 diabetes mellitus and stage 2-3 chronic kidney disease (CKD). This study aimed to explore the efficacy of rosuvastatin in the female TRACK-D population. METHODS: This study was a gender-based analysis of 2,998 patients (1,044 females) enrolled in the TRACK-D study and were randomized to short-term (2 days before and 3 days after procedure) rosuvastatin therapy or standard of care...
May 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27097221/beneficial-effects-of-sarpogrelate-and-rosuvastatin-in-high-fat-diet-streptozotocin-induced-nephropathy-in-mice
#7
Dong-Hyun Kim, Bo-Hyun Choi, Sae-Kwang Ku, Jeong-Hyeon Park, Euichaul Oh, Mi-Kyoung Kwak
Chronic kidney disease (CKD) is a major complication of metabolic disorders such as diabetes mellitus, obesity, and hypertension. Comorbidity of these diseases is the factor exacerbating CKD progression. Statins are commonly used in patients with metabolic disorders to decrease the risk of cardiovascular complications. Sarpogrelate, a selective antagonist of 5-hydroxytryptamine (5-HT) 2A receptor, inhibits platelet aggregation and is used to improve peripheral circulation in diabetic patients. Here, we investigated the effects of sarpogrelate and rosuvastatin on CKD in mice that were subjected to a high fat diet (HFD) for 22 weeks and a single low dose of streptozotocin (STZ, 40 mg/kg)...
2016: PloS One
https://www.readbyqxmd.com/read/26222855/rosuvastatin-treatment-for-preventing-contrast-induced-acute-kidney-injury-after-cardiac-catheterization-a-meta-analysis-of-randomized-controlled-trials
#8
REVIEW
You Yang, Yan-Xian Wu, Yun-Zhao Hu
We performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the protective effects of rosuvastatin on contrast-induced acute kidney injury (CI-AKI) and major adverse cardiovascular events (MACEs) in patients undergoing cardiac catherization.PubMed, MEDLINE, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Central RCTs were searched for RCTs from inception to May 2015, to compare rosuvastatin for preventing CI-AKI with placebo treatment in patients undergoing cardiac catherization...
July 2015: Medicine (Baltimore)
https://www.readbyqxmd.com/read/26156625/a-trial-of-pitavastatin-versus-rosuvastatin-for-dyslipidemia-in-chronic-kidney-disease
#9
RANDOMIZED CONTROLLED TRIAL
Masanori Abe, Noriaki Maruyama, Takashi Maruyama, Kazuyoshi Okada, Masayoshi Soma
AIM: To determine the lipid lowering effectiveness, cost effectiveness, and safety of rosuvastatin compared with pitavastatin in dyslipidemic patients with concurrent renal disorders. METHODS: This single-center, prospective, open-label, randomized, 12-month study evaluated rosuvastatin (2.5 mg) and pitavastatin (1 or 2 mg) in 134 dyslipidemic patients with concurrent chronic kidney disease (CKD; rosuvastatin group, n=68; pitavastatin group, n=66). Lipid parameters [i...
2015: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/26037614/statins-can-improve-proteinuria-and-glomerular-filtration-rate-loss-in-chronic-kidney-disease-patients-further-reducing-cardiovascular-risk-fact-or-fiction
#10
REVIEW
Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P Mikhailidis
INTRODUCTION: The prevalence of chronic kidney disease (CKD), a risk factor for cardiovascular disease (CVD), is increasing worldwide. Statin treatment, the cornerstone of prevention or treatment of CVD, might have beneficial effects on urine protein excretion and renal function as determined by the glomerular filtration rate, whereas it might protect from acute kidney injury (AKI), mainly due to contrast-induced AKI. These beneficial effects on CKD may not be drug class effects; specific statins at specific doses may help prevent CKD deterioration and reduce CVD risk...
2015: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/25979868/high-intensity-statin-therapy-in-patients-with-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#11
REVIEW
Yu-Ling Yan, Bo Qiu, Jing Wang, Song-Bai Deng, Ling Wu, Xiao-Dong Jing, Jian-Lin Du, Ya-Jie Liu, Qiang She
OBJECTIVE: To evaluate the efficacy and safety of high-intensity statin therapy in patients with chronic kidney disease (CKD). DESIGN: A systematic review and meta-analysis. DATA SOURCES: Randomised controlled trials (RCTs) comparing high-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20/40 mg) with moderate/mild statin treatment or placebo were derived from the databases (PubMed, Embase, Ovid, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, and ISI Web of Knowledge)...
2015: BMJ Open
https://www.readbyqxmd.com/read/25758273/short-term-rosuvastatin-treatment-for-the-prevention-of-contrast-induced-acute-kidney-injury-in-patients-receiving-moderate-or-high-volumes-of-contrast-media-a-sub-analysis-of-the-track-d-study
#12
RANDOMIZED CONTROLLED TRIAL
Jian Zhang, Yi Li, Gui-Zhou Tao, Yun-Dai Chen, Tao-Hong Hu, Xue-Bin Cao, Quan-Min Jing, Xiao-Zeng Wang, Ying-Yan Ma, Geng Wang, Hai-Wei Liu, Bin Wang, Kai Xu, Jing Li, Jie Deng, Ya-Ling Han
BACKGROUND: Current randomized trials have demonstrated the effects of short-term rosuvastatin therapy in preventing contrast-induced acute kidney injury (CIAKI). However, the consistency of these effects on patients administered different volumes of contrast media is unknown. METHODS: In the TRACK-D trial, 2998 patients with type 2 diabetes and concomitant chronic kidney disease (CKD) who underwent coronary/peripheral arterial angiography with or without percutaneous intervention were randomized to short-term (2 days before and 3 days after procedure) rosuvastatin therapy or standard-of-care...
March 20, 2015: Chinese Medical Journal
https://www.readbyqxmd.com/read/25739954/differential-effects-of-strong-and-regular-statins-on-the-clinical-outcome-of-patients-with-chronic-kidney-disease-following-coronary-stent-implantation%C3%A3-the-kumamoto-intervention-conference-study-kics-registry
#13
MULTICENTER STUDY
Masanobu Ishii, Seiji Hokimoto, Tomonori Akasaka, Kazuteru Fujimoto, Yuji Miyao, Koichi Kaikita, Shuichi Oshima, Koichi Nakao, Hideki Shimomura, Ryusuke Tsunoda, Toyoki Hirose, Ichiro Kajiwara, Toshiyuki Matsumura, Natsuki Nakamura, Nobuyasu Yamamoto, Shunichi Koide, Hideki Oka, Yasuhiro Morikami, Naritsugu Sakaino, Kunihiko Matsui, Hisao Ogawa
BACKGROUND: The aim of this study was to examine the effects of different statins on the clinical outcomes of Japanese patients with coronary stent implants. METHODS AND RESULTS: This study included 5,801 consecutive patients (males, 4,160; age, 69.7±11.1 years, mean±SD) who underwent stent implantation between April 2008 and March 2011. They were treated with a strong statin (n=3,042, 52%, atorvastatin, pitavastatin, or rosuvastatin), a regular statin (n=1,082, 19%, pravastatin, simvastatin, or fluvastatin) or no statin (n=1,677, 29%)...
2015: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/25670636/impact-of-rosuvastatin-on-contrast-induced-acute-kidney-injury-in-patients-at-high-risk-for-nephropathy-undergoing-elective-angiography
#14
RANDOMIZED CONTROLLED TRIAL
Okay Abaci, Alev Arat Ozkan, Cuneyt Kocas, Gokhan Cetinkal, Osman Sukru Karaca, Onur Baydar, Aysem Kaya, Tevfik Gurmen
Although statins have been shown to prevent contrast-induced acute kidney injury in patients with acute coronary syndromes, the benefit of statins is not known for patients at high risk for nephropathy who undergo elective coronary angiography. Two hundred twenty consecutive statin-naive patients with chronic kidney disease (estimated glomerular filtration rate <60 ml/min/1.73 m(2)) who underwent elective coronary or peripheral angiography were randomly assigned to receive rosuvastatin (40 mg on admission, followed by 20 mg/day; n = 110) or no statin treatment (control group, n = 110)...
April 1, 2015: American Journal of Cardiology
https://www.readbyqxmd.com/read/25660356/renal-effects-of-atorvastatin-and-rosuvastatin-in-patients-with-diabetes-who-have-progressive-renal-disease-planet-i-a-randomised-clinical-trial
#15
RANDOMIZED CONTROLLED TRIAL
Dick de Zeeuw, Deborah A Anzalone, Valerie A Cain, Michael D Cressman, Hiddo J Lambers Heerspink, Bruce A Molitoris, John T Monyak, Hans-Henrik Parving, Giuseppe Remuzzi, James R Sowers, Donald G Vidt
BACKGROUND: The role of lipid-lowering treatments in renoprotection for patients with diabetes is debated. We studied the renal effects of two statins in patients with diabetes who had proteinuria. METHODS: PLANET I was a randomised, double-blind, parallel-group trial done in 147 research centres in Argentina, Brazil, Bulgaria, Canada, Denmark, France, Hungary, Italy, Mexico, Romania, and the USA. We enrolled patients with type 1 or type 2 diabetes aged 18 years or older with proteinuria (urine protein:creatinine ratio [UPCR] 500-5000 mg/g) and taking stable angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both...
March 2015: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/25357250/comparison-of-the-efficacy-of-rosuvastatin-versus-atorvastatin-in-preventing-contrast-induced-nephropathy-in-patient-with-chronic-kidney-disease-undergoing-percutaneous-coronary-intervention
#16
COMPARATIVE STUDY
Yong Liu, Yuan-hui Liu, Ning Tan, Ji-yan Chen, Ying-ling Zhou, Li-wen Li, Chong-yang Duan, Ping-yan Chen, Jian-fang Luo, Hua-long Li, Wei-Guo
OBJECTIVES: We prospectively compared the preventive effects of rosuvastatin and atorvastatin on contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI). METHODS: We enrolled 1078 consecutive patients with CKD undergoing elective PCI. Patients in Group 1 (n = 273) received rosuvastatin (10 mg), and those in group 2 (n = 805) received atorvastatin (20 mg). The primary end-point was the development of CIN, defined as an absolute increase in serum creatinine ≥0...
2014: PloS One
https://www.readbyqxmd.com/read/25343843/statins-for-the-prevention-of-contrast-induced-acute-kidney-injury
#17
REVIEW
Timothy Ball, Peter A McCullough
Acute kidney injury (AKI) is a common medical problem, especially in patients undergoing cardiovascular procedures. The risk of kidney damage has multiple determinants and is often related to or exacerbated by intravenous or intra-arterial iodinated contrast. Contrast-induced AKI (CI-AKI) has been associated with an increased risk of subsequent myocardial infarction, stroke, the development of heart failure, rehospitalization, progression of chronic kidney disease, end-stage renal disease, and death. Statins have been studied extensively in the setting of chronic kidney disease and they have been shown to reduce albuminuria, but they have had no effect on the progressive reduction of glomerular filtration or the need for renal replacement therapy...
2014: Nephron. Clinical Practice
https://www.readbyqxmd.com/read/25015912/rosuvastatin-preserves-renal-function-and-lowers-cystatin-c-in-hiv-infected-subjects-on-antiretroviral-therapy-the-saturn-hiv-trial
#18
RANDOMIZED CONTROLLED TRIAL
Chris T Longenecker, Corrilynn O Hileman, Nicholas T Funderburg, Grace A McComsey
BACKGROUND: In chronic human immunodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glomerular filtration rate such as inflammation. Statins may improve cystatin C by improving glomerular function or by decreasing inflammation. METHODS: The Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial randomized 147 patients on stable antiretroviral therapy (ART) with low-density lipoprotein cholesterol ≤130 mg/dL to blinded 10 mg daily rosuvastatin or placebo...
October 15, 2014: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/24788803/benefit-risk-assessment-of-rosuvastatin-in-the-treatment-of-atherosclerosis-and-related-diseases
#19
REVIEW
Michael S Kostapanos, Christos V Rizos, Moses S Elisaf
Rosuvastatin has been marketed for approximately a decade. In this review we critically discuss available evidence on the benefits and risks from its use. In clinical trials using rosuvastatin, 'lowest is best' was relevant for on-treatment low-density lipoprotein cholesterol levels. Targeting levels <50 mg/dl was associated with the greatest decrease in vascular morbidity/mortality in the primary prevention setting. Also, such reduction can induce atherosclerosis regression without increasing the risk of adverse effects...
July 2014: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/24685964/an-update-on-the-benefits-and-risks-of-rosuvastatin-therapy
#20
REVIEW
Peter P Toth
Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) that reduces low-density lipoprotein cholesterol levels to the greatest extent of all currently marketed statins. Prospective, randomized studies demonstrate the ability of rosuvastatin to reduce the risk of cardiovascular events and stabilize atherosclerosis. However, the efficacy of rosuvastatin in patient subpopulations (eg, patients with chronic kidney disease, women, ethnic subgroups) is not well described in the literature...
March 2014: Postgraduate Medicine
keyword
keyword
64572
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"